Our partners
Since its creation, OT4B has put its trust in French and European actors for the entire drug development process. The complete drug delivery chain therefore represents the excellence of French pharmaceutical research and development.
We accentuate the contribution of each of our partners in order to design, with them, the best-suited solutions for patients and for our projects.
Key scientific partners
An exclusive partnership with Toulouse University Hospital
OT4B has been in a strategic partnership with Toulouse University Hospital since 2018, focused on the continuation and development of academic research work led by Professor Maithé Tauber’s team at the Rare Diseases Reference Centre for Prader-Willi Syndrome and other rare forms of obesity with eating disorders (CRMR PRADORT), particularly via financing and operational support in the implementation of clinical studies for the oxytocin development programme in Prader-Willi syndrome.
Toulouse University Hospital: academic sponsor of the principal clinical studies conducted on oxytocin
Toulouse University Hospital is the sponsor of the OTBB3 study, through the Clinical Research and Innovation Unit (DRCI). The DRCI is part of the Research and Innovation Direction (DRI) and is in charge of monitoring and evaluating the clinical research work carried out by the institution, while ensuring that good clinical practices are observed.
Rare Diseases Reference Centre for Prader-Willi Syndrome and other rare forms of obesity with eating disorders (CRMR PRADORT): principal coordinator of ‘OTBB3’
As part of the federation of Rare Diseases Reference Centres within Toulouse University Hospital, CRMR PRADORT is coordinated by Professor Maithé Tauber and was accredited in 2004 and again in 2017.
The centre is the main coordinator of the OTBB3 study, for which it provides scientific and medical expertise on Prader-Willi syndrome. It plays an advisory and coordinating role for the investigating centres involved in the study.
INSERM Transfert
In July 2020, OT4B obtained the operating license for a family of patents on the use of oxytocin in the treatment of Prader-Willi syndrome, of which Professor Maithé Tauber is a co-inventor.
The licence agreement was negotiated and signed by Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm (the French National Institute of Health and Medical Research), Aix-Marseille University and Toulouse University Hospital.
A strong commitment to Occitania
OT4B is strongly committed to supporting the French economy and creating value in France and more specifically in Occitania, the region where the company was created.
Focus on...
A key partner for our clinical supply operations
Find out how Creapharm managed the set-up and clinical supply operations (IMP and sampling kits) in the OTBB3 phase III clinical trial, working hand in hand with OT4B to solve many complex business challenges…
